Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients

M. DAI; Tsu-Yi Chao; T. Chao; C. Chiu; Y. Lu; H. Shiah; Y. Wu; G. Gerald Fetterly; N. Hung; D.L. Cutler; R. Kwan; D. Douglas Kramer; W. Chan; T. Hung

Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients

M. DAI, Tsu-Yi Chao, T. Chao, C. Chiu, Y. Lu, H. Shiah, Y. Wu, G. Gerald Fetterly, N. Hung, D.L. Cutler, R. Kwan, D. Douglas Kramer, W. Chan, T. Hung

Research output: Contribution to journal › Article › peer-review

Abstract

Intravenous (IV) paclitaxel is approved for the treatment of numerous cancers including MBC. Oraxol (Athenex, USA), is an oral formulation of paclitaxel in combination with a novel, orally active, potent and specific inhibitor of P-gp (HM30181A). Oraxol is expected to be less toxic with comparable efficacy to its iv counterpart. We report the interim results of an ongoing study of Oraxol in MBC patients.

Original language	English
Journal	Annals of Oncology
Publication status	Published - Oct 21 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Oral-paclitaxel-and-HM30181A-demonstrate-clinical-activity-in-metastatic-breast-cancer-MBC-patients

Cite this

DAI, M., Chao, T.-Y., Chao, T., Chiu, C., Lu, Y., Shiah, H., Wu, Y., Gerald Fetterly, G., Hung, N., Cutler, D. L., Kwan, R., Douglas Kramer, D., Chan, W., & Hung, T. (2018). Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients. Annals of Oncology. https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Oral-paclitaxel-and-HM30181A-demonstrate-clinical-activity-in-metastatic-breast-cancer-MBC-patients

DAI, M, Chao, T-Y, Chao, T, Chiu, C, Lu, Y, Shiah, H, Wu, Y, Gerald Fetterly, G, Hung, N, Cutler, DL, Kwan, R, Douglas Kramer, D, Chan, W & Hung, T 2018, 'Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients', Annals of Oncology. <https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Oral-paclitaxel-and-HM30181A-demonstrate-clinical-activity-in-metastatic-breast-cancer-MBC-patients>

@article{c37e951a06c9408f9c3697e058b3a3b8,

title = "Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients",

abstract = "Intravenous (IV) paclitaxel is approved for the treatment of numerous cancers including MBC. Oraxol (Athenex, USA), is an oral formulation of paclitaxel in combination with a novel, orally active, potent and specific inhibitor of P-gp (HM30181A). Oraxol is expected to be less toxic with comparable efficacy to its iv counterpart. We report the interim results of an ongoing study of Oraxol in MBC patients.",

author = "M. DAI and Tsu-Yi Chao and T. Chao and C. Chiu and Y. Lu and H. Shiah and Y. Wu and {Gerald Fetterly}, G. and N. Hung and D.L. Cutler and R. Kwan and {Douglas Kramer}, D. and W. Chan and T. Hung",

year = "2018",

month = oct,

day = "21",

language = "English",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients

AU - DAI, M.

AU - Chao, Tsu-Yi

AU - Chao, T.

AU - Chiu, C.

AU - Lu, Y.

AU - Shiah, H.

AU - Wu, Y.

AU - Gerald Fetterly, G.

AU - Hung, N.

AU - Cutler, D.L.

AU - Kwan, R.

AU - Douglas Kramer, D.

AU - Chan, W.

AU - Hung, T.

PY - 2018/10/21

Y1 - 2018/10/21

N2 - Intravenous (IV) paclitaxel is approved for the treatment of numerous cancers including MBC. Oraxol (Athenex, USA), is an oral formulation of paclitaxel in combination with a novel, orally active, potent and specific inhibitor of P-gp (HM30181A). Oraxol is expected to be less toxic with comparable efficacy to its iv counterpart. We report the interim results of an ongoing study of Oraxol in MBC patients.

AB - Intravenous (IV) paclitaxel is approved for the treatment of numerous cancers including MBC. Oraxol (Athenex, USA), is an oral formulation of paclitaxel in combination with a novel, orally active, potent and specific inhibitor of P-gp (HM30181A). Oraxol is expected to be less toxic with comparable efficacy to its iv counterpart. We report the interim results of an ongoing study of Oraxol in MBC patients.

M3 - Article

SN - 0923-7534

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this